A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

The decision comes after CMS cut nearly 300 people, about 5 percent of its workforce ... Reuters’ Bhanvi Satija reports that Sarepta Therapeutics won’t comply with the FDA’s request to stop shipping ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

A local nonprofit is navigating uncertainty with several programs on the chopping block. Disability Rights Ohio serves as an advocate for people with disabilities. They help with jobs, education, ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...

GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...